首页 > 抗体蛋白 > 抗体
Alexa Fluor® 488 anti-mouse/human CD11b Antibo
产品名称:
Alexa Fluor® 488 anti-mouse/human CD11b Antibo
产品类别:
抗体
产品编号:
101219
产品应用:
101219
[价格]
规格 价格 库存
25µg ¥ 1212 1

产品详情

Product Details

Verified Reactivity
Mouse, Human, Cynomolgus, Rhesus
Reported Reactivity
Chimpanzee, Baboon, Rabbit
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
C57BL/10 splenocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography and conjugated with Alexa Fluor? 488 under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
IHC-F, 3D IHC - Verified

SB - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 ?g per 106 cells in 100 ?l volume. For immunohistochemical staining on frozen tissue sections, the suggested use of this reagent is 2.5 - 10 ?g per ml. For 3D immunohistochemistry on formalin-fixed tissues, a concentration of 5.0 ?g/mL is suggested. It is recommended that the reagent be titrated for optimal performance for each application.

* Alexa Fluor? 488 has a maximum emission of 519 nm when it is excited at 488 nm.


Alexa Fluor? and Pacific Blue? are trademarks of Life Technologies Corporation.

View full statement regarding label licenses
Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone M1/70 has been verified for?immunocytochemistry (ICC) and frozen immunohistochemistry (IHC-F).

Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1,4, in vitro blocking3,9,12, depletion2,8, immunofluorescence microscopy6,7,10, immunohistochemistry of acetone-fixed frozen sections5,11-13, and spatial biology (IBEX)35,36. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) (Cat. No. 101248).

Additional Product Notes

Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

Application References

(PubMed link indicates BioLegend citation)
  1. Springer T, et al. 1978. Eur. J. Immunol. 8:539. (IP)
  2. Ault K and Springer T. 1981. J. Immunol. 126:359. (Deplete)
  3. Springer TA, et al. 1982. Immunol. Rev. 68:171. (Block)
  4. Ho MK and Springer TA. 1983. J. Biol. Chem. 258:2766. (IP)
  5. Flotte TJ, et al. 1983. Am. J. Pathol. 111:112. (IHC)
  6. Noel GJ, et al. 1990. J. Clin. Invest. 85:208. (IF)
  7. Allen LA and Aderem A. 1996. J. Exp. Med. 184:627 (IF)
  8. D'Amico A and Wu L. 2003. J. Exp. Med. 198:293. (Deplete)
  9. Brickson SJ, et al. 2003. Appl Physiol. 95:969. (Block)
  10. Clatworthy MR and Smith KG. 2004. J. Exp. Med. 199:717. (IF)
  11. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  12. Zhang Y, et al. 2002. J. Immunol. 168:3088. (IHC)
  13. Iwasaki A and Kelsall BL. 2001. J. Immunol. 166:4884 (IHC, FC)
  14. Tailleux L. 2003. J. Exp. Med. 197:121. (Block, FC)
  15. Olver S, et al. 2006. Cancer Research 66:571. (FC)
  16. Tan SL, et al. 2006. J. Immunol. 176:2872. (FC) PubMed
  17. Ponomarev ED, et al. 2006. J. Immunol. 176:1402. (FC)
  18. Dzhagalov I, et al. 2007. Blood 109:1620. (FC)
  19. Fazilleau N, et al. 2007. Nature Immunol. 8:753.
  20. Rasmussen JW, et al. 2006. Infect. Immun.74:6590. PubMed
  21. Napimoga MH, et al. 2008. J. Immunol. 180:609. PubMed
  22. Elqaraz-Carmon V, et al. 2008. J. Lipid. Res. 49:1894. PubMed
  23. Kim DD, et al. 2008. Blood 112:1109. PubMed
  24. Guo Y, et al. 2008. Blood 112:480. PubMed
  25. Norian LA, et al. 2009. Cancer Res. 69:3086. (FC) PubMed
  26. Baumgartner CK, et al. 2010. J. Immunol. 184:573. PubMed
  27. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  28. Whiteland J, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
  29. Weber GF, et al. 2014. J Exp Med. 211:1243. PubMed
  30. Ashok A, et al. 2015. Toxicol Sci. 143:64. PubMed
  31. Price PJ, et al. 2015. J Immunol. 194:1164. PubMed
  32. Doni A, et al. 2015. J Exp Med. 212:905. PubMed
  33. Ferreira R, et al. 2016. J Infect Dis. 213: 669 - 673. PubMed
  34. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
  35. Radtke?AJ,?et al.?2020.?Proc Natl Acad Sci U S A.?117:33455-65. (SB)?PubMed
  36. Radtke?AJ,?et al.?2022.?Nat Protoc.?17:378-401. (SB)?PubMed
Product Citations
  1. Vella JL, et al. 2021. Life Sci Alliance. 4:. PubMed
  2. Laura C Burzynski et al. 2019. Immunity. 50(4):1033-1042 . PubMed
  3. Suzuki K, et al. 2019. Cell Mol Gastroenterol Hepatol. 8:119. PubMed
  4. Wang Q, et al. 2022. Nat Commun. 13:3022. PubMed
  5. Schwartz C, et al. 2014. J Immunol. 193:3590. PubMed
  6. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  7. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
  8. Ooi JD, et al. 2019. Nat Commun. 10:3392. PubMed
  9. Yu X, et al. 2021. Nature. 594:560. PubMed
  10. Barberio AE, et al. 2020. ACS Nano. 14:11238. PubMed
  11. Hickman SE, et al. 2019. Methods Mol Biol. 2034:305. PubMed
  12. Rangan P et al. 2019. Cell reports. 26(10):2704-2719 . PubMed
  13. Zhang H, et al. 2017. Leukemia. 10.1128/mBio.00226-17. PubMed
  14. Onishi S, et al. 2015. PLoS One. 10:126564. PubMed
  15. Sun P, et al. 2021. J Invest Dermatol. 141:1542. PubMed
  16. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  17. Jumabay M, et al. 2022. Sci Rep. 12:5614. PubMed
  18. Hilpert C, et al. 2016. J Immunol. 197: 2780 - 2786. PubMed
  19. Lin JR et al. 2018. eLife. 7 pii: e31657. PubMed
  20. Simonneau M, et al. 2018. Oncotarget. 9:36457. PubMed
  21. Chen C, et al. 2019. Cell Rep. 29:4200. PubMed
  22. Jiang H, et al. 2016. J Immunol. 197: 2880 - 2890. PubMed
  23. Pan RY, et al. 2019. Sci Adv. 5:eaau6328. PubMed
  24. Mooney C, et al. 2017. International Journal of Molecular Sciences. 10.3390/ijms18051037. PubMed
  25. Zhou L, et al. 2021. Transl Cancer Res. 10:5307. PubMed
  26. Ganguly K, et al. 2022. Front Immunol. 13:930449. PubMed
  27. Cheng Q, et al. 2020. Nat Nanotechnol. 0.842361111. PubMed
  28. Lin M, et al. 2019. Mol Med Rep. 19:1622. PubMed
  29. Cui H, et al. 2020. JCI Insight. 5:. PubMed
  30. Ullah I, et al. 2021. Immunity. 54:2143. PubMed
  31. Usui H, et al. 2007. Diabetes. 56:363. PubMed
  32. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  33. Fran?a TT, et al. 2021. JCI Insight. 6:. PubMed
  34. Zhou L, et al. 2021. Transl Cancer Res. 10:3364. PubMed
  35. Venosa A, et al. 2015. Am J Physiol Lung Cell Mol Physiol. 309: L1487 - L1498. PubMed
  36. Rai MA, et al. 2020. Retrovirology. 17:35. PubMed
  37. He J, et al. 2019. J Clin Invest. 130. PubMed
  38. Gong Y, et al. 2020. J Neuroinflammation. 0.845833333. PubMed
  39. Namiguchi K, et al. 2022. Front Cardiovasc Med. 8:761591. PubMed
  40. Kar S, Colino J, Snapper C 2016. J Immunol. 196: 4204 - 4213. PubMed
  41. Li X, et al. 2020. Aging Dis. 0.821527778. PubMed
  42. Huang L, et al. 2018. Exp Neurol. 300:41. PubMed
  43. Cheng HW, et al. 2022. Nat Commun. 13:2027. PubMed
  44. Cai B, et al. 2020. Cell Metabolism. 31(2):406-421.e7.. PubMed
  45. Miyajima M,et al. 2017. Nat Immunol.. 10.1038/ni.3867. PubMed
  46. Bochenek MA, et al. 2018. Nat Biomed Eng. 2:810. PubMed
  47. Berry MR et al. 2017. Cell. 170(5):860-874 . PubMed
  48. von Roemeling CA, et al. 2020. Nat Commun. 11:1508. PubMed
  49. Dymek B, et al. 2022. J Inflamm Res. 15:5621. PubMed
  50. Georgiadou A, et al. 2022. Elife. 11:. PubMed
  51. Sparber F, et al. 2019. Cell Host Microbe. 25:389. PubMed
  52. Wu X, et al. 2020. Front Immunol. 1.922222222. PubMed
  53. Roychoudhury J, et al. 2010. Invest Ophthalmol Vis Sci. 51:3560. PubMed
  54. McAusland TM, et al. 2021. Mol Ther Oncolytics. 20:306. PubMed
  55. Panka D, et al. 2013. Mol Cancer. 12:17. PubMed
  56. Silva HM, et al. 2019. J Exp Med. 216:786. PubMed
  57. Garg BK, et al. 2019. PLoS One. 14:e0214942. PubMed
  58. Yamada K, et al. 2016. Cancer Res . 76: 4283 - 4292. PubMed
  59. Chmielewski M and Abken H 2017. Cell Rep.. 10.1016/j.celrep.2017.11.063. PubMed
  60. Stone S et al. 2018. Glia. 66(7):1331-1345 . PubMed
  61. Hsing CH, et al. 2021. Biomedicines. 9:. PubMed
  62. Chung EJ, et al. 2021. Int J Radiat Oncol Biol Phys. 110:526. PubMed
  63. Kim SH, et al. 2020. Neoplasia. 1.3375. PubMed
RRID
AB_493545 (BioLegend Cat. No. 101219) AB_389305 (BioLegend Cat. No. 101217)

Antigen Details

Structure
Integrin family, associates with integrin β2 (CD18), 170 kD
Distribution

Granulocytes, monocytes/macrophages, dendritic cells, NK cells, subsets of T and B cells

Function
Adhesion, chemotaxis
Ligand/Receptor
ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4 (CD242), iC3b, fibrinogen
Cell Type
B cells, Dendritic cells, Granulocytes, Macrophages, Monocytes, Neutrophils, NK cells, T cells, Tregs
Biology Area
Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity, Neuroscience, Neuroscience Cell Markers
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Springer TA. 1994. Cell 76:301.
3. Coxon A, et al. 1996. Immunity 5:653.

Gene ID
16409 View all products for this Gene ID 3684 View all products for this Gene ID
UniProt
View information about CD11b on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线